US3840663A - 5-alkylpipecolic acids as anti-hypertensive agents - Google Patents

5-alkylpipecolic acids as anti-hypertensive agents Download PDF

Info

Publication number
US3840663A
US3840663A US00237527A US23752772A US3840663A US 3840663 A US3840663 A US 3840663A US 00237527 A US00237527 A US 00237527A US 23752772 A US23752772 A US 23752772A US 3840663 A US3840663 A US 3840663A
Authority
US
United States
Prior art keywords
alkylpipecolic
acids
trans
blood pressure
hypertensive agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00237527A
Inventor
P Jones
P Somani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US00237527A priority Critical patent/US3840663A/en
Application granted granted Critical
Publication of US3840663A publication Critical patent/US3840663A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Definitions

  • This invention relates to a method of treating hypertension using 5-alkylpipecolic acids as the antihypertensive agents.
  • 5-Alkylpipecolic acids have previously been reported to be useful as intermediates in the preparation of certain quinolizidines, and as anesthetics and antibacterial agents. It has now been found that compounds of the formula lCOOH wherein R is C -C alkyl or a salt thereof are useful in lowering blood pressure in hypertensive patients.
  • C -C alkyl refers to both straight and branched chain alkyl groups having from 1 to 8 carbon atoms, and including methyl, ethyl, npropyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl and the like.
  • salts refers to salts such as the alkali metal, alkaline earth metal, ammonium and substituted ammonium salts including the sodium, potassium, lithium, calcium, magnesium, barium, methyl ammonium, diethylammonium, benzylammonium, triethanol ammonium salts and the like, as well as the pharmaceutically acceptable acid addition salts including the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate and the like.
  • Such salts are prepared by methods well known in the art.
  • the compounds useful in the practice of this invention have been separated into the cisand trans-isomers While the mixture and the trans-isomers exhibit antihypertensive activity, the cis-isomers are inactive as antihypertensive agents.
  • the compounds useful in the practice of this invention exhibit activity by both the oral and intraperitioneal routes; however, the oral route is the preferred route of administration. Accordingly, the compounds of this invention are administered to hypertensive patients at dosages of from 0.1 to mg./kg. of body weight daily, preferably in divided doses, i.e., three to four times daily.
  • the presently preferred compound is dl-trans-S-n-butylpipecolic acid which reduced blood pressure in spontaneously hypertensive rats up to 18% for 28 hours after oral administration of 10 mg./kg. dose.
  • suitable agents useful in the practice of this invention include S-methylpipecolic acid, S-n-propylpipecolic acid, S-neopentylpipecolic acid, S-n-hexylpipecolic acid and the like.
  • the 5-alkylpipecolic acids can be co-administered with, for example, diuretics or tranquilizers.
  • the compounds can be administered alone, that is, as the sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like.
  • the oral dosage forms are prepared by methods well known in the art, and generally include a pharmaceutically acceptable carrier or diluent such as lactose, starch or sucrose, along with lubricating agents such as magnesium stearate and flavoring and sweetening agents and the like.
  • the dosage forms for parenteral administration are also prepared by methods well known in the art.
  • a method of lowering blood pressure in hypertensive patient comprising administering a therapeutically effective amount of a compound selected from the group consisting of the trans isomer and a mixture of the trans and cis isomers represented by the formula J COOH wherein R is C -C alkyl or a salt thereof to said patient.
  • a compound selected from the group consisting of the trans isomer and a mixture of the trans and cis isomers represented by the formula J COOH wherein R is C -C alkyl or a salt thereof to said patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

WHEREIN R IS C1-C8 ALKYL OR A SALT THEREOF TO SAID PATIENT.

2-(HOOC-),5-R1-PIPERIDINE

1. A METHOD OF LOWERING BLOOD PRESSURE IN HYPERTENSIVE PATIENT COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF THE TRANS ISOMER AND A MIXTURE OF THE TRANS AND CIS ISOMERS REPRESENTED BY THE FORMULA

Description

United States Patent 3,840,663 S-ALKYLPIPECOLIC ACIDS AS ANTI- HY PERTENSIVE AGENTS Peter Hadley Jones, Lake Forest, and Pitambar Somani,
Libertlylyille, 111., assignors to Abbott Laboratories, Chicago,
No Drawing. Filed Mar. 23, 1972, Ser. No. 237,527 Int. Cl. A61]: 27/00 US. Cl. 424-267 3 Claims ABSTRACT OF THE DISCLOSURE A method of lowering blood pressure in hypertensive patients comprising administering a therapeutically effective amount of a compound of the formula l \N o 0 OH wherein R is C -C alkyl or a salt thereof.
DETAILED DESCRIPTION OF THE INVENTION This invention relates to a method of treating hypertension using 5-alkylpipecolic acids as the antihypertensive agents.
5-Alkylpipecolic acids have previously been reported to be useful as intermediates in the preparation of certain quinolizidines, and as anesthetics and antibacterial agents. It has now been found that compounds of the formula lCOOH wherein R is C -C alkyl or a salt thereof are useful in lowering blood pressure in hypertensive patients.
As used herein, the term C -C alkyl refers to both straight and branched chain alkyl groups having from 1 to 8 carbon atoms, and including methyl, ethyl, npropyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl and the like.
The term salts refers to salts such as the alkali metal, alkaline earth metal, ammonium and substituted ammonium salts including the sodium, potassium, lithium, calcium, magnesium, barium, methyl ammonium, diethylammonium, benzylammonium, triethanol ammonium salts and the like, as well as the pharmaceutically acceptable acid addition salts including the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, valerate, oleate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate and the like. Such salts are prepared by methods well known in the art.
The synthesis of the S-alkylpipecolic acids is disclosed in French Patent No. M1599 1963) and in Arch. Pharm. (Weinheim) 301 (10); 728-35 (1968).
The compounds useful in the practice of this invention have been separated into the cisand trans-isomers While the mixture and the trans-isomers exhibit antihypertensive activity, the cis-isomers are inactive as antihypertensive agents.
"Ice
The antihypertensive activity of the compounds useful in the practice of this invention was first established in the spontaneously hypertensive rat procedure, Tabei et al.,
Clin. Pharmac. Therap., 11 (2); 269-274 (1970), wherein significant decreases in blood pressure were observed at oral dosages of 10 mg./kg. of body weight and I at 30 mg./kg. i.p.
The compounds useful in the practice of this invention exhibit activity by both the oral and intraperitioneal routes; however, the oral route is the preferred route of administration. Accordingly, the compounds of this invention are administered to hypertensive patients at dosages of from 0.1 to mg./kg. of body weight daily, preferably in divided doses, i.e., three to four times daily.
The presently preferred compound is dl-trans-S-n-butylpipecolic acid which reduced blood pressure in spontaneously hypertensive rats up to 18% for 28 hours after oral administration of 10 mg./kg. dose. However, other suitable agents useful in the practice of this invention include S-methylpipecolic acid, S-n-propylpipecolic acid, S-neopentylpipecolic acid, S-n-hexylpipecolic acid and the like.
As is the case with other antihypertensive agents, the 5-alkylpipecolic acids can be co-administered with, for example, diuretics or tranquilizers.
While the compounds can be administered alone, that is, as the sole component of a filled capsule, it is preferred to formulate the compound in various dosage forms for oral or parenteral administration such as tablets, syrups, sterile aqueous or non-aqueous suspensions and the like. The oral dosage forms are prepared by methods well known in the art, and generally include a pharmaceutically acceptable carrier or diluent such as lactose, starch or sucrose, along with lubricating agents such as magnesium stearate and flavoring and sweetening agents and the like. The dosage forms for parenteral administration are also prepared by methods well known in the art.
We claim:
1. A method of lowering blood pressure in hypertensive patient comprising administering a therapeutically effective amount of a compound selected from the group consisting of the trans isomer and a mixture of the trans and cis isomers represented by the formula J COOH wherein R is C -C alkyl or a salt thereof to said patient. 2. The method of Claim 1 wherein said compound is S-n-butylpipecolic acid.
3. The method of Claim 1 wherein said compound is dl-trans-S-n-butylpipecolic acid.
References Cited Clin. Pharmac. & Therap., 11(2); 269-274 (1970).
ALBERT T. MEYERS, Primary Examiner D. M. STEPHENS, Assistant Examiner US. Cl. X.R. 424263 Patented Oct. 8, 197 4

Claims (1)

1. A METHOD OF LOWERING BLOOD PRESSURE IN HYPERTENSIVE PATIENT COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF THE TRANS ISOMER AND A MIXTURE OF THE TRANS AND CIS ISOMERS REPRESENTED BY THE FORMULA
US00237527A 1972-03-23 1972-03-23 5-alkylpipecolic acids as anti-hypertensive agents Expired - Lifetime US3840663A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00237527A US3840663A (en) 1972-03-23 1972-03-23 5-alkylpipecolic acids as anti-hypertensive agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00237527A US3840663A (en) 1972-03-23 1972-03-23 5-alkylpipecolic acids as anti-hypertensive agents

Publications (1)

Publication Number Publication Date
US3840663A true US3840663A (en) 1974-10-08

Family

ID=22894108

Family Applications (1)

Application Number Title Priority Date Filing Date
US00237527A Expired - Lifetime US3840663A (en) 1972-03-23 1972-03-23 5-alkylpipecolic acids as anti-hypertensive agents

Country Status (1)

Country Link
US (1) US3840663A (en)

Similar Documents

Publication Publication Date Title
EP0498069B1 (en) New use of peptide derivative
US7550507B2 (en) 2-(alpha-hydroxypentyl) benzoate and its preparation and use
TWI293249B (en) A medical composition containing aspirin
CZ286325B6 (en) N-(endo-9-methyl-9-azabicyclo/3,3,1/non-3-yl)-1-methylindazole-3-carboxamide, use thereof for preparing a pharmaceutical preparation and the pharmaceutical preparation containing thereof
JPH02255652A (en) Benzenesulfonamides and preparation thereof
US4831054A (en) 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
US4053617A (en) 2,1,3-benzothiadiazoles as myolonolytics
US4389415A (en) Method of treating hypertension
US4806567A (en) Method for the treatment of ischemia and reperfusion syndromes
US3840663A (en) 5-alkylpipecolic acids as anti-hypertensive agents
EP1459747A2 (en) Method of inhibiting biosynthesis of Elf5A
KR20020007188A (en) Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
US3966978A (en) 4-Biphenylacetic acid as an inhibitor of platelet aggregation
JPH0152366B2 (en)
US4148878A (en) Inhibition of platelet aggregation with selected phosphoric acid esters
AU2018390274B2 (en) Therapeutic agent for glaucoma comprising FP agonist and β blocker
US4016288A (en) Compositions and method of treating hypertension
JPS6140205B2 (en)
US3764679A (en) Iodinin as an anti-hypertensive agent
US4363809A (en) Organic compounds
AU603765B2 (en) Carboxy azetidine derivatives for use in the reduction of blood cholesterol levels
JPH0513928B2 (en)
US3857949A (en) Prophylaxis and treatment of cardiac disorders
JPH078864B2 (en) 2-alkyl-3-benzoylbenzofuran
KR920003580B1 (en) Prophylactic and curing composition for arteriosclerosis